Copanlisib
Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
49/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 34/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Recurrent Primary Peritoneal Endometrioid Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Roswell Park Cancer Institute | Phase 2/3 | B |
Inno-206 National Cancer Institute (NCI) | Phase 2/3 | B |
(+)-VINCRISTINE Roswell Park Cancer Institute | Phase 2/3 | B |
Pembrolizumab Roswell Park Cancer Institute | Phase 2 | B |
Cyclophosphamide Roswell Park Cancer Institute | Phase 2 | B |
View all 14 →
Same molecule, other indications
Copanlisib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →